TrialFrontiers in immunology2024

Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile.

Paul Chamberlain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.